Literature DB >> 19079657

Alendronate-induced esophagitis in an elderly woman.

Victoria Gómez1, Shu-Yuan Xiao.   

Abstract

Ingestion of alendronate sodium (Fosamax) had been reported to sometimes cause erosive or ulcerative esophagitis. Despite its widespread use and several case reports describing the clinical and endoscopic presentation, there has been limited discussion on the histologic appearances of the esophagitis caused by the medication. Here we describe one case of an elderly woman who presented with alendronate-induced esophagitis. The histopathologic changes that make this case unique are the large, "bizarre" squamous epithelial cells and scattered dyskaratotic cells, two findings not well described in previous reports. These unique features add to the histologic spectrum of alendronate-induced esophageal injury, and shall help differentiating this type of esophagitis from those with other etiologies.

Entities:  

Keywords:  Alendronate sodium; Fosamax; esophagitis

Year:  2008        PMID: 19079657      PMCID: PMC2583639     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  10 in total

1.  Alendronate-associated esophagitis: endoscopic and pathologic features.

Authors:  A Ribeiro; K R DeVault; J T Wolfe; M E Stark
Journal:  Gastrointest Endosc       Date:  1998-06       Impact factor: 9.427

2.  From the Food and Drug Administration.

Authors:  S L Nightingale
Journal:  JAMA       Date:  1996 May 22-29       Impact factor: 56.272

3.  Alendronate-associated esophageal injury: pathologic and endoscopic features.

Authors:  S C Abraham; M Cruz-Correa; L A Lee; J H Yardley; T T Wu
Journal:  Mod Pathol       Date:  1999-12       Impact factor: 7.842

4.  Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.

Authors:  E Siris; R S Weinstein; R Altman; J M Conte; M Favus; A Lombardi; K Lyles; H McIlwain; W A Murphy; C Reda; R Rude; M Seton; R Tiegs; D Thompson; J R Tucci; A J Yates; M Zimering
Journal:  J Clin Endocrinol Metab       Date:  1996-03       Impact factor: 5.958

Review 5.  Pill esophagitis.

Authors:  J W Kikendall
Journal:  J Clin Gastroenterol       Date:  1999-06       Impact factor: 3.062

6.  Multinucleated epithelial giant cell changes in esophagitis: a clinicopathologic study of 14 cases.

Authors:  S P Singh; R D Odze
Journal:  Am J Surg Pathol       Date:  1998-01       Impact factor: 6.394

7.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

Review 8.  Esophagitis associated with the use of alendronate.

Authors:  P C de Groen; D F Lubbe; L J Hirsch; A Daifotis; W Stephenson; D Freedholm; S Pryor-Tillotson; M J Seleznick; H Pinkas; K K Wang
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

Review 9.  What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates.

Authors:  David Y Graham
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

10.  Esophageal irritation due to alendronate sodium tablets: possible mechanisms.

Authors:  C P Peter; L K Handt; S M Smith
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

  10 in total
  3 in total

1.  Aspiration of alendronic acid leading to localized bronchiectasis.

Authors:  Gordon I A MacDonald; Graeme P Currie; David M Reid
Journal:  Eur J Clin Pharmacol       Date:  2011-10-19       Impact factor: 2.953

2.  Chemical injury caused by acute alendronic acid aspiration.

Authors:  Zoe Victoria Ottaway; Cara Hammond; Simon Merritt
Journal:  BMJ Case Rep       Date:  2014-04-30

Review 3.  Design and Biological Evaluation of Delivery Systems Containing Bisphosphonates.

Authors:  Blessing Aderibigbe; Isiaka Aderibigbe; Patricia Popoola
Journal:  Pharmaceutics       Date:  2016-12-26       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.